Study Title
A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week
Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in
Patients with Diabetic Gastroparesis
Purpose
Extension study for RLM-MD-02 participants. To compare the efficacy of relamorelin with placebo in participants after 12 weeks of treatment. Total of 24 weeks (12 weeks from RLM-MD-02 study and 12 weeks from this study)
Eligibility
Participant met all inclusion/exclusion criteria in RLM-MD-02 and successfully completed the study
Able to provide written informed consent (IC) prior to any study procedures and willing and able to comply with study procedures
You Cannot:
Be planning to receive an investigational drug (other than study treatment) or investigational device at any time during Study RLM-MD-03
Have an unresolved AE or a clinically significant finding on physical examination, clinical laboratory test, or 12-lead ECG that, in the investigator’s opinion, would limit the participant’s ability to participate in or complete the study
Study Process
Study Duration: 46 weeks
Interested in more information on clinical research? Contact WK Physician Network Clinical Research at 318-212-8613
Trial Details
Investigator:
IRB:
Copernicus
IRB Number:
Trial Type:
Drug
Sponsor:
Allergan
Contact Information:
Interested in Volunteering for the Study?
If you would like more information about this study, please call us at (318) 212-8671.